PharmiNews

The Directory of Pharma Companies and News

Vertex

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.

Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. For additional information and the latest updates from the company, please visit www.vrtx.com.

Category: Biotech
Category: Biotech

Vertex News

DateNews
2017-08-01FDA Approves KALYDECO® (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Resid...
2017-07-26Vertex Reports Second-Quarter 2017 Financial Results
2017-07-25Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656
2017-07-18Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic ...
2017-07-17Vertex Awards Two First-Generation College Students Full Scholarships to the University of Massachusetts
2017-07-13Vertex to Announce Second Quarter 2017 Financial Results on July 26
2017-07-13Vertex Announces Reimbursement Agreement in Italy for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the U...
2017-06-09Vertex to Present at the Goldman Sachs Healthcare Conference on June 13
2017-06-09Vertex Announces Nine Presentations of Data on ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) at the European...
2017-06-08Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors
2017-06-01Vertex Announces Long-Term Reimbursement Agreement with the Republic of Ireland for ORKAMBI® (lumacaftor/ivacaftor), KAL...
2017-05-19Vertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their Immediate Family Members
2017-05-18Vertex to Present at the UBS Healthcare Conference on May 23
2017-05-17FDA Approves KALYDECO® (ivacaftor) for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Resid...
2017-05-04Vertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis
2017-04-27Vertex Reports First-Quarter 2017 Financial Results
2017-04-12Vertex to Announce First Quarter 2017 Financial Results on April 27
2017-03-28Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significa...
2017-03-06Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
2017-03-02Vertex to Present at the Cowen Healthcare Conference on March 6
2017-01-25Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results
2017-01-11Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex
2017-01-08Vertex Provides Update on Business and Financial Performance and Research and Development Programs
2017-01-04Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year...
2016-12-19Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Und...
2016-11-07Positive Phase 3 Study of ORKAMBI® in Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies of the F508del Mutatio...
2016-11-02Vertex to Present at the Credit Suisse Healthcare Conference on November 8
2016-10-27Vertex Presents Long-Term Data Demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) Show the Pot...
2016-10-25Vertex Reports Third Quarter 2016 Financial Results
2016-10-25Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Tr...
2016-10-07Vertex to Announce Third Quarter 2016 Financial Results on October 25
2016-09-28U.S. Food and Drug Administration Approves ORKAMBI® (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages...
2016-08-15Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic F...
2016-07-27Vertex Reports Second Quarter 2016 Financial Results
2016-07-14Vertex to Announce Second Quarter 2016 Financial Results on July 27
2016-07-06Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics™ for Cystic Fibrosis
2016-06-10Vertex Announces Presentations of Data for KALYDECO® (ivacaftor) and ORKAMBI® (lumacaftor/ivacaftor) at European Cystic ...
2016-05-31U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI® (lumacaftor/ivacaftor) in...
2016-05-31Vertex to Present at the Goldman Sachs Healthcare Conference on June 7
2016-04-27Vertex Reports First Quarter 2016 Financial Results
2016-04-15Vertex to Announce First Quarter 2016 Financial Results on April 27
2016-03-10Vertex to Present at the Barclays Healthcare Conference on March 15
2016-03-08Vertex Receives Australian Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Caus...
2016-02-24Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic F...
2016-02-05Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis A...
2016-01-27Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results
2016-01-26Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fi...
2016-01-10Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for th...
2015-11-23Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer
2015-11-23Vertex to Present at the Piper Jaffray Healthcare Conference on December 1
2015-11-20Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cys...
2015-11-18Vertex Receives Two EU Approvals for KALYDECO® (ivacaftor) for People with Cystic Fibrosis
2015-11-04Vertex to Present at the Credit Suisse Healthcare Conference on November 10
2015-10-28Vertex Reports Third Quarter 2015 Financial Results
2015-10-26Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develo...
2015-10-09Vertex to Announce Third Quarter 2015 Financial Results on October 28
2015-10-08Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Major...
2015-10-07Supplemental New Drug Application for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older who h...
2015-09-25Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) in the European Uni...
2015-09-08Vertex to Present at the Morgan Stanley Healthcare Conference on September 16
2015-08-19Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massach...
2015-07-29Vertex Reports Second Quarter 2015 Financial Results
2015-07-14Vertex to Announce Second Quarter 2015 Financial Results on July 29
2015-07-02FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for P...
2015-07-02ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cys...
2015-06-18Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors
2015-06-11Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference
2015-06-04Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibr...
2015-06-03Vertex to Present at the Goldman Sachs Healthcare Conference on June 11
2015-05-17New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People wi...
2015-05-13Vertex to Present at the UBS Healthcare Conference on May 19
2015-05-12Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Tr...
2015-04-29Vertex Reports First Quarter 2015 Financial Results
2015-04-09Vertex to Announce First Quarter 2015 Financial Results on April 29
2015-03-23Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fi...
2015-03-18Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ag...
2015-02-11Vertex to Present at Upcoming Investor Conferences
2015-01-28Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015
2015-01-11Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatm...
2015-01-06Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year...
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.